Peter Goldstein, Executive Director of Vaccine Platform Development. Peter has 18 years of experience managing multidisciplinary scientific and technical programs. He plays a central role in management of ILiAD’s assay development, clinical serology, and Quality Management System, and is responsible for many of ILiAD’s non-pertussis indications, including Asthma and Tuberculosis. Following his work with anti-cancer peptides in the laboratory of Nobel Laureate Andrew Schally, he co-founded Biscayne Pharmaceuticals in 2012 (later becoming Biscayne Neurotherapeutics). At Biscayne, he was responsible for R&D and Clinical Operations, managing global drug development programs in oncology and epilepsy. In these roles he oversaw clinical epilepsy trials, GMP manufacturing of peptides and small molecules, pharmacokinetics & toxicology studies in multiple species, development of novel in-vitro assays, pre-clinical oncology studies, buildout of quality systems and SOP development. He also supported due diligence and intellectual property, resulting in a successful business exit strategy.
He began his career as a technical product manager at Ceradyne, Inc., and has overseen Phase 1-4 clinical trials in various consulting roles. Peter holds B.S. and M.S. degrees in Materials Science and Engineering from the University of Florida.